A pharmaceutical company is boosting jobs by up to 60 per cent with a laboratory expansion at its site in Tredegar.

The facility is global pharmaceutical outsourcing services provider PCI Pharma Services' development and manufacturing centre of excellence with specialist expertise in the processing of highly potent molecules.

The site has undergone significant investments over recent years and this latest project ensures analytical capacity and capability to service increasing customer demand.

The investment will see PCI’s laboratory increase its analyst headcount by approximately 60 per cent and increase its High-Performance Liquid Chromatography capacity by more than 20 per cent, in addition to tripling its capacity for sample receipt.

Since launching its contained manufacturing facility using the latest in containment technology at Tredegar, the site has seen significant growth in its global customer base.

This latest project will ensure that PCI is able to service both existing and potential new clients, as well as offering a project initiation in terms of analytical transfer within four to six weeks.

PCI senior vice president, international Richard Yarwood said: “Expansion of our laboratory services is an important program for the Tredegar site. Speed to market is of critical importance to our clients.

"We pride ourselves on continually improving our service for both existing and potential new clients and our analytical service is integral from the early stages of analytical development through to commercial launch and the associated annual stability testing.

“Among our many key strengths is our ability to on-board projects faster than our competitors. This additional footprint will ensure we are able to continue to offer this speed of project initiation addressing customer need.”